clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Otitis Media with Effusion D010034 9 associated lipids
Otitis Media D010033 12 associated lipids
Osteomyelitis D010019 10 associated lipids
Psittacosis D009956 4 associated lipids
Endophthalmitis D009877 12 associated lipids
Nocardia Infections D009617 6 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nasal Polyps D009298 26 associated lipids
Myxoma D009232 1 associated lipids
Myocardial Infarction D009203 21 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Metaplasia D008679 7 associated lipids
Mastoiditis D008417 2 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mycetoma D008271 4 associated lipids
Lymphangitis D008205 4 associated lipids
Lymphadenitis D008199 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stjepanovic MI et al. Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. 2016 Infez Med pmid:28011973
Abuhammour A et al. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. 2016 Arab J Gastroenterol pmid:27665525
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Gisbert JP Helicobacter pylori-related diseases. 2016 Gastroenterol Hepatol pmid:27888863
Rossi A et al. Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. 2016 Drug Dev Ind Pharm pmid:26065531
Harada T et al. Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. 2016 J. Pharmacol. Exp. Ther. pmid:27489022
Bonfigli AR et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. 2016 Nutr Metab Cardiovasc Dis pmid:27480449
Orrin E et al. Sporotrichoid Mycobacterium chelonae. 2016 Australas. J. Dermatol. pmid:27469486
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Mitchell H and Katelaris P Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. 2016 Med. J. Aust. pmid:27256648
Ullah S et al. Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. 2016 Drug Deliv pmid:27247018
Kuo CH et al. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. 2016 Medicine (Baltimore) pmid:27227911
Sluch IM et al. Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. 2016 Cornea pmid:27227391
Matsumoto H et al. Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. 2016 Helicobacter pmid:27061611
Tsaganos T et al. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. 2016 Antimicrob. Agents Chemother. pmid:27044546
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Melia MT and Auwaerter PG Time for a Different Approach to Lyme Disease and Long-Term Symptoms. 2016 N. Engl. J. Med. pmid:27028918
Tepeš B et al. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. 2016 Eur J Gastroenterol Hepatol pmid:26862930
Lim SG et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. 2016 Dig Liver Dis pmid:26856963
Niv Y Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. 2016 Digestion pmid:26849820
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Qiu XH et al. Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. 2016 Acta Haematol. pmid:26505646
Ghaith D et al. Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. 2016 J Chemother pmid:26358218
Li Y et al. Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection. 2015 Drug Deliv pmid:24471983
Sobajima T et al. A Case of Pulmonary Actinomycosis Associated With Aspiration of Cedar Leaves. 2015 J Bronchology Interv Pulmonol pmid:26165898
Gunjan S et al. Clarithromycin enhances the antimalarial efficacy of mefloquine via its increased bioavailability and disrupting P. falciparum apicoplast. 2015 Life Sci. pmid:26164186
Tongtawee T et al. Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. 2015 Asian Pac. J. Cancer Prev. pmid:26163609
Fujimura S et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. 2015 J. Infect. Chemother. pmid:26162777
Converse PJ et al. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. 2015 PLoS Negl Trop Dis pmid:26042792
Klain V and Timmerman L Comment on The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:26034875
Prapitpaiboon H et al. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26028098
Nayyar E and Taimur S Sporotrichoid lesions: an age-old conundrum. 2015 Am. J. Med. pmid:26021809
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Heo J et al. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. 2015 J. Gastroenterol. Hepatol. pmid:25867608
Sugita S et al. EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. 2015 Biochem. Biophys. Res. Commun. pmid:25858318
Kesselheim AS et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. 2015 J Gen Intern Med pmid:25855479
Gianni C Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. 2015 G Ital Dermatol Venereol pmid:25854670
Zhang S et al. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. 2015 Cancer Lett. pmid:25853150
Iino Y et al. Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. 2015 Acta Otolaryngol. pmid:25649881
Streetman DS and Stout SM Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? 2015 CMAJ pmid:25646282
Ang TL et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. 2015 J. Gastroenterol. Hepatol. pmid:25639278
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Kim H et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 Ann. Hematol. pmid:25501820
Keshavarz Azizi Raftar S et al. The Helicobacter pylori resistance rate to clarithromycin in Iran. 2015 Microb. Drug Resist. pmid:25144338
Chan CC et al. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. 2015 BMC Gastroenterol pmid:26635102
Hsu PI et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. 2015 Medicine (Baltimore) pmid:26632893
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Kiesewetter B et al. Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. 2015 J. Clin. Oncol. pmid:24778391
Zhang W et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. 2015 Gut pmid:26338726
Fasciana T et al. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. 2015 J. Med. Microbiol. pmid:26338221